Cargando…
P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429589/ http://dx.doi.org/10.1097/01.HS9.0000969368.47239.5b |
_version_ | 1785090752626294784 |
---|---|
author | Liang, Emily Hirayama, Alexandre Kimble, Erik Portuguese, Andrew Albittar, Aya Chapuis, Aude Shadman, Mazyar Till, Brian Cassaday, Ryan Milano, Filippo Kiem, Hans-Peter Turtle, Camesron Maloney, David Gauthier, Jordan |
author_facet | Liang, Emily Hirayama, Alexandre Kimble, Erik Portuguese, Andrew Albittar, Aya Chapuis, Aude Shadman, Mazyar Till, Brian Cassaday, Ryan Milano, Filippo Kiem, Hans-Peter Turtle, Camesron Maloney, David Gauthier, Jordan |
author_sort | Liang, Emily |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10429589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104295892023-08-17 P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL Liang, Emily Hirayama, Alexandre Kimble, Erik Portuguese, Andrew Albittar, Aya Chapuis, Aude Shadman, Mazyar Till, Brian Cassaday, Ryan Milano, Filippo Kiem, Hans-Peter Turtle, Camesron Maloney, David Gauthier, Jordan Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429589/ http://dx.doi.org/10.1097/01.HS9.0000969368.47239.5b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Posters Liang, Emily Hirayama, Alexandre Kimble, Erik Portuguese, Andrew Albittar, Aya Chapuis, Aude Shadman, Mazyar Till, Brian Cassaday, Ryan Milano, Filippo Kiem, Hans-Peter Turtle, Camesron Maloney, David Gauthier, Jordan P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL |
title | P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL |
title_full | P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL |
title_fullStr | P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL |
title_full_unstemmed | P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL |
title_short | P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL |
title_sort | p616: long-term follow-up update and multivariable analyses of factors associated with duration of response after cd19 car t-cell therapy for relapsed/refractory cll |
topic | Posters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429589/ http://dx.doi.org/10.1097/01.HS9.0000969368.47239.5b |
work_keys_str_mv | AT liangemily p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT hirayamaalexandre p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT kimbleerik p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT portugueseandrew p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT albittaraya p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT chapuisaude p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT shadmanmazyar p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT tillbrian p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT cassadayryan p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT milanofilippo p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT kiemhanspeter p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT turtlecamesron p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT maloneydavid p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll AT gauthierjordan p616longtermfollowupupdateandmultivariableanalysesoffactorsassociatedwithdurationofresponseaftercd19cartcelltherapyforrelapsedrefractorycll |